Home-Use LED Light Therapy Patents: Who Leads, Trends 2026
- 70.2% concentration. The top 5 of 57 ranked assignees hold 181 of 258 records in scope — a field where a handful of filers set the terms for everyone else.
- Filings are climbing again. After a lull, filings rose from 7 in 2021 to 13 in 2024, an 86% increase over that span, even as the leader's own recent-year output has gone quiet.
- Electrotherapy claims dominate. 87.6% of the 258 records sit in A61N (electrotherapy & radiation), leaving diagnostic integration and informatics layers comparatively open.
Filing growth compares 2021 (7 records) with 2024 (13) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 258 records in scope (CR5), not by the ranked leaders only.
What the home-use LED light therapy patent record shows
Home-use LED light therapy sits at the intersection of consumer electronics and clinical phototherapy: devices that once required a dermatologist’s office now ship as masks, wands and panels sold direct to consumers. The 258 records in scope, filed between 2015 and mid-2026, trace how that shift has been claimed — irradiance control, wavelength selection, treatment-duration logic, and the eye-protection and certification features that separate a consumer device from a medical one.
Filing activity peaked in 2018 at 32 records and has since settled into a lower but recovering pattern, with growth concentrated in a small number of assignees. Publication lags filing by roughly 18 months, so the 2025-2026 figures in this dataset are still filling in and should not be read as a slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 258 records: how filing volume has moved year over year, and how those filings distribute across IPC subclasses.
Filing trend, 2017-2026
Filings ran from 20 in 2017 to a peak of 32 in 2018, cooled through the early 2020s, then rebounded — 7 filings in 2021 climbing to 13 in 2024, an 86% increase. The 2026 figure (2 so far) is a partial year and will rise as later publications land.
IPC subclass composition
A61N (electrotherapy & radiation therapy) covers 87.6% of the 258 records, confirming this is fundamentally an electrotherapy field first. A61B (diagnosis & surgery) appears in 32.6%, and A61F (implants & prostheses) in 13.2%; each record can carry several classes, so these shares add to more than 100%.
Shares are the percentage of the 258 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Home-Use LED Light Therapy with Eureka
This page is one run against one query. Ask Eureka your own question about home-use led light therapy and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited prior art and a recent filing
Photobiomodulation device for accelerating surgical rehabilitation and method thereof
A photobiomodulation device mounted on a mobile structure with an irradiator carrying multiple LED treatment panels and an adjustable arm for positioning over a target anatomical region. The LEDs emit red, blue, yellow and infrared light at predefined wavelengths, with onboard sensors for temperature and distance, a treatment-protocol interface, safety interruption, data logging and LED calibration.Filed by Elixir MD Inc., published 2026-08-13 as US20260233020A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20080033519A1 | Light generating device for intravascular use | 245 |
| 2 | US20060030908A1 | Skin treatment phototherapy device | 178 |
| 3 | US20080091250A1 | Light therapy desk lamp | 171 |
| 4 | US5500009A | Method of treating herpes | 148 |
| 5 | US20080103563A1 | Light therapy personal care device | 141 |
| 6 | US20080119913A1 | Light therapy personal care device | 135 |
| 7 | US20080103560A1 | Ultraviolet indicator light therapy device | 106 |
| 8 | US20130066404A1 | Light therapy platform system | 99 |
| 9 | WO2024013267A1 | Wearable and automated ultrasound therapy devices and methods | 81 |
| 10 | US20080065056A1 | Skin treatment phototherapy method | 81 |
Citation counts favour older records simply by virtue of time in the corpus; treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and composition mean for filing strategy
Three figures from this dataset matter more than the rest for anyone deciding where to file or partner next.
A small group sets the claim boundaries
With 181 of 258 records held by five assignees, most of the fundamental irradiance, wavelength-selection and treatment-duration claim space is already occupied. New entrants competing head-on in that core territory face dense prior art from a small set of well-established filers.
Renewed filing activity after a lull
Filing volume fell from the 2018 peak of 32 before recovering through the early 2020s. The rise from 7 to 13 filings between 2021 and 2024 suggests renewed commercial interest, even though the field's largest historical filer shows no output in the latest year captured.
Electrotherapy claims dominate; adjacent classes are thin
A61N covers the large majority of records, but G16H (healthcare informatics, 4.3%), A61H (physical therapy & massage, 1.9%) and A61L (sterilising & disinfecting, 1.6%) are each claimed by only a handful of filers, pointing to comparatively open ground around software-driven protocol management and device hygiene.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to home-use led light therapy, with the prior art for and against each one.
Who holds the ground, and where the field is still open
The assignee ranking covers 57 companies counted across the 258 records in scope — the full list the dataset returns, not a top-50 or top-100 cut.
One filer dominates by volume
The leading assignee's 128 records dwarf the rest of the ranking; fifth place holds 9 and tenth place holds 6, showing a steep drop-off rather than a gradual taper.
A tight cluster of joint filings
Co-filing activity is concentrated among a small group of related entities, with the strongest pairing appearing in 9 shared records. This points to a compact web of affiliated filers rather than broad industry-wide collaboration.
Everyone else files singly
Beyond the top 10, the remaining 47 ranked assignees account for the balance of records, largely as single or few-record filers. That long tail is where opportunistic, narrowly scoped filings still register.
| Assignee | Recent year | YoY |
|---|---|---|
| Johnson & Johnson Consumer Inc. | 0 | — |
| LA LUMIERE LLC | 0 | — |
| Lumiport LLC | 0 | — |
| Ellex Medical | 0 | — |
| POWELL STEVEN D | 0 | — |
| YOUNGBLOOD JIMMY | 0 | — |
| SMITH ANDREW MICHAEL | 0 | — |
| RAYBALANCE INC | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, partnership scouting, or identifying open claim territory.
Map freedom-to-operate against the top filers
With 70.2% of records held by five assignees, any new filing in core irradiance or wavelength-selection claims should be checked against that concentrated set before development spend goes further.
Run a freedom-to-operate check in EurekaTrack the recovering filing trend
The 2021-2024 rise from 7 to 13 filings suggests the field is re-accelerating; monitoring new entrants over the next few publication cycles will show whether that momentum holds.
Set up filing alerts in EurekaExplore the under-claimed branches
Informatics, sterilisation and combination-therapy claims sit well below the electrotherapy core in filing density, offering room for differentiated claims rather than head-on competition.
Explore white space in EurekaFrequently asked questions
It is highly concentrated. Of 57 ranked assignees covering 258 records in scope, the top 5 alone account for 181 records, or 70.2% of the total. The top 10 push that to 84.5%. That means most core claim territory around irradiance output, wavelength selection and treatment duration is already held by a small number of filers, and new entrants should expect dense prior art in that core space.
Filing activity is recovering after a mid-period dip. Volume peaked at 32 records in 2018, declined through the early 2020s, then rose from 7 filings in 2021 to 13 in 2024, an 86% increase over that span. The 2025 and 2026 figures in the dataset are still incomplete because publication typically lags filing by around 18 months, so the most recent years should not be read as a slowdown.
The bulk of filing activity, 87.6% of the 258 records, sits in A61N electrotherapy and radiation-therapy claims. Adjacent classes such as G16H healthcare informatics (4.3%), A61H physical therapy and massage (1.9%), and A61L sterilising and disinfecting (1.6%) carry far fewer filings. That gap suggests treatment-protocol software, hygiene features and combination-therapy devices are comparatively open ground for new claims.
The ranking covers 57 assignees across the 258 records in scope, with one company holding 128 records, a distant fifth place at 9 records and tenth place at 6. That steep drop-off from the leader indicates one dominant filer rather than several closely matched competitors. Recent-year momentum data, however, shows zero output from several of the historically largest filers in the latest year captured, which is worth checking before assuming continued dominance.
US20260233020A1, filed by Elixir MD Inc. and published in August 2026, describes a photobiomodulation device with multi-panel LED irradiation, an adjustable positioning arm, onboard temperature and distance sensing, and protocol-selection software with safety interruption and calibration features. It illustrates how newer filings are layering sensing and software control on top of established electrotherapy claims. Anyone developing a similar combination of hardware and dosing software should review this filing's specific claim scope before finalising a design.
Research Home-Use LED Light Therapy in depth with Eureka
Go past this page: query the whole home-use led light therapy corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.